Retrospective evaluation of sirolimus (mTOR blocker) for lymphatic malformations presenting in the neonatal period: a single-center experience.
4 affiliations
- 1Department of Surgical Diseases of Childhood Named After G.A.Bairov, St. Petersburg State Pediatric Medical University, St. Petersburg, Russia.
- 2Department of Oncology, Pediatric Oncology and Radiation Therapy, St. Petersburg State Pediatric Medical University, St. Petersburg, Russia.
- 3Perinatal Center of the St. Petersburg State Pediatric Medical University, St. Petersburg, Russia.
- 4Department of Oncohematology, St. Petersburg State Pediatric Medical University, St. Petersburg, Russia.
Abstract
Background
Lymphatic malformations are rare vascular anomalies. Currently, there is no uniform approach to the treatment of these patients. Neonates with extensive disease often suffer from multiple complications, organ dysfunction, and various tissue lesions, which may be life-threatening and lead to aesthetic deformity. Treatment with sirolimus has the potential to improve symptoms and downsize the lesion, up to complete regression. This retrospective single-center study presents our experience with oral sirolimus in the treatment of newborns with lymphatic malformations, evaluating its efficacy and safety.Methods
A retrospective analysis was conducted on 23 patients in the neonatal period and early infancy with lymphatic malformations, treated at the St. Petersburg State Pediatric Medical University between 2021 and 2025. Seven patients underwent primary radical surgical treatment and were not included in the analysis. The final study cohort consisted of 16 patients who received primary conservative therapy with sirolimus. Fifteen out of 16 patients started receiving oral sirolimus before the age of 28 days of life. The median age at the commencement of treatment was 15 days after birth. After instrumental and laboratory examination, sirolimus was administered at a starting reduced dose of 0.5 mg/m²/day divided into two daily doses, followed by a gradual increase under clinical and laboratory monitoring. The therapeutic concentration of sirolimus in the blood (5-15 ng/mL) was monitored once a week.Results
Disease stabilization or regression was achieved in all 16 patients (100%), with a partial or complete radiological response (≥50% volume reduction) in 13 patients (81.25%) and complete regression (>90% volume reduction) in 10 patients (62.5%) at the 6-month assessment. No treatment-related serious adverse events requiring permanent discontinuation were observed. Recorded adverse events included transient respiratory infections (n = 2), diarrhea (n = 2), aphthous stomatitis (n = 1), and mild anemia (n = 1), all of which resolved with supportive care or temporary dose adjustment.Conclusion
In this selected cohort, sirolimus demonstrated an acceptable safety and efficacy profile, supporting its feasibility as a conservative first-line strategy in neonates with extensive or unresectable lymphatic malformations. However, larger prospective studies are needed to confirm these findings.
Related
- Sirolimus in Patients with Overgrowth, with or without Vascular Malformations: The SIPA-SOS Study
- Contrast‑enhanced ultrasound-guided sclerotherapy of vascular malformations in the head and neck: Initial clinical experience in a paediatric case series
- CO105 | THALIDOMIDE FOR RECURRENT GASTROINTESTINAL BLEEDING IN RARE BLEEDING DISORDERS AND VENOUS MALFORMATIONS: A MONOCENTRIC EXPERIENCE
- Efficacy and safety of portable ultrasound-guided pingyangmycin sclerotherapy for deep-seated oral and maxillofacial venous malformations: a retrospective observational study.
- Understanding the experience of healthcare providers in delivering care to older adults presenting in emergency departments: a qualitative study.
BibTeX
@article{podkamenev2026retrospective,
title = {{Retrospective evaluation of sirolimus (mTOR blocker) for lymphatic malformations presenting in the neonatal period: a single-center experience.}},
author = {Alexey Podkamenev and Arina Syrtsova and Gleb Kondratiev and Victor Nabokov and Roman Ti and Svetlana Kuzminykh and Vladislav Dvoretsky and Ani Ajamoghlian and Alexander Kostylev and Irina Myznikova},
journal = {Frontiers in pediatrics},
year = {2026},
month = oct,
doi = {10.3389/fped.2026.1900903},
url = {https://europepmc.org/article/MED/42909030},
note = {CC BY},
}
RIS
TY - JOUR
TI - Retrospective evaluation of sirolimus (mTOR blocker) for lymphatic malformations presenting in the neonatal period: a single-center experience.
AU - Alexey Podkamenev
AU - Arina Syrtsova
AU - Gleb Kondratiev
AU - Victor Nabokov
AU - Roman Ti
AU - Svetlana Kuzminykh
AU - Vladislav Dvoretsky
AU - Ani Ajamoghlian
AU - Alexander Kostylev
AU - Irina Myznikova
PY - 2026
DA - 2026/10/07
JO - Frontiers in pediatrics
DO - 10.3389/fped.2026.1900903
UR - https://europepmc.org/article/MED/42909030
AB - Background Lymphatic malformations are rare vascular anomalies. Currently, there is no uniform approach to the treatment of these patients. Neonates with extensive disease often suffer from multiple complications, organ dysfunction, and various tissue lesions, which may be life-threatening and lead to aesthetic deformity. Treatment with sirolimus has the potential to improve symptoms and downsize the lesion, up to complete regression. This retrospective single-center study presents our experience with oral sirolimus in the treatment of newborns with lymphatic malformations, evaluating its efficacy and safety.Methods A retrospective analysis was conducted on 23 patients in the neonatal period and early infancy with lymphatic malformations, treated at the St. Petersburg State Pediatric Medical University between 2021 and 2025. Seven patients underwent primary radical surgical treatment and were not included in the analysis. The final study cohort consisted of 16 patients who received primary conservative therapy with sirolimus. Fifteen out of 16 patients started receiving oral sirolimus before the age of 28 days of life. The median age at the commencement of treatment was 15 days after birth. After instrumental and laboratory examination, sirolimus was administered at a starting reduced dose of 0.5 mg/m²/day divided into two daily doses, followed by a gradual increase under clinical and laboratory monitoring. The therapeutic concentration of sirolimus in the blood (5-15 ng/mL) was monitored once a week.Results Disease stabilization or regression was achieved in all 16 patients (100%), with a partial or complete radiological response (≥50% volume reduction) in 13 patients (81.25%) and complete regression (>90% volume reduction) in 10 patients (62.5%) at the 6-month assessment. No treatment-related serious adverse events requiring permanent discontinuation were observed. Recorded adverse events included transient respiratory infections (n = 2), diarrhea (n = 2), aphthous stomatitis (n = 1), and mild anemia (n = 1), all of which resolved with supportive care or temporary dose adjustment.Conclusion In this selected cohort, sirolimus demonstrated an acceptable safety and efficacy profile, supporting its feasibility as a conservative first-line strategy in neonates with extensive or unresectable lymphatic malformations. However, larger prospective studies are needed to confirm these findings.
SN - 2296-2360
ER -